- Home
- SCOR vs INKT Comparison
SCOR vs INKT Comparison
Compare SCOR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCOR | INKT |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.8M | 51.7M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCOR | INKT |
|---|---|---|
| Price | $7.15 | $11.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 7.3K | ★ 19.4K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $358,940,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $1.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $4.39 | $4.56 |
| 52 Week High | $10.18 | $76.00 |
Technical Indicators
Market Signals| Indicator | SCOR | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 42.73 |
| Support Level | $6.51 | $10.99 |
| Resistance Level | $7.15 | $12.27 |
| Average True Range (ATR) | 0.34 | 0.82 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 73.75 | 28.98 |
Price Performance
Historical ComparisonAbout SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each across media platforms. The platforms it measures include televisions, mobile devices, computers, tablets, CTV devices, and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada, and other regions. It provides solutions for the automotive, digital media, financial services, pharmaceutical, retail, technology, travel, and other industries.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.